Evidence map›Paper›PMID 40406353›Full record

ArticleFrontiers in pediatrics2025

Management of a pediatric patient with rapidly progressive glomerulonephritis and cutaneous mucormycosis: a case report.

Lili Jia, Kaili Shi, Xiaoyi Sun, Feng Xu, Tao Sun, Chunlin Gao

Abstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lili JiaDepartment of Pediatrics, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Kaili Shi *Department of Pediatrics, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
Xiaoyi Sun *Department of Pediatrics, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Feng XuNational Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing, China.
Tao SunDepartment of Pediatrics, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Chunlin GaoDepartment of Pediatrics, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucormycosis is a highly invasive and rare opportunistic infection caused by mucor fungi, characterized by challenging diagnosis and rapid disease progression. It predominantly affects patients with compromised immune systems due to various reasons, such as kidney failure, long-term use of antibiotics or corticosteroids. We recently successfully treated a pediatric patient with rapidly progressive glomerulonephritis accompanied by severe cutaneous mucormycosis. To our knowledge, this is the first reported case of rapidly progressive glomerulonephritis nephritis accompanied by dermatophytosis in a pediatric patient. In this case, we share our management experience, including special nursing experience. Cutaneous mucormycosis progresses quickly and is difficult to diagnose and treat, especially in children with compromised immune function, warranting high vigilance from clinicians and nursing staff. Early diagnosis and targeted treatment are crucial for improving the prognosis of patients. Therefore, once there is a suspicion of a mucormycosis infection, we recommend the early application of various testing methods such as fungal culture, skin biopsy and genetic testing in order to to promptly confirm the diagnosis.

Indexed as

compromised immune functioncutaneous mucormycosismanagementpediatricrapidly progressive glomerulonephritis

Identifiers

PMID40406353
PMCPMC12094951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.